Search research articles
Contact Us
Filters
Showing results (251-260 of 293) with videos related to
Page
of 30
Sort By:
Journal of Neurology
|
September 8, 2025
Factors associated with early response to efgartigimod in patients with generalized myasthenia gravis: a multicenter retrospective observational study
Wenjia Zhu, Yuping Chen, Cong Tian, et al.
Molecular Cancer
|
May 1, 2025
Multi‑omics analysis identifies different molecular subtypes with unique outcomes in early-stage poorly differentiated lung adenocarcinoma
Bing Liu, Wei Tao, Xuantong Zhou, et al.
Journal of Medical Genetics
|
November 3, 2023
Non-coding CGG repeat expansion in <i>LOC642361/NUTM2B-AS1</i> is associated with a phenotype of oculopharyngodistal myopathy
Xinyu Gu, Jiaxi Yu, Kexin Jiao, et al.
Journal of Medicinal Chemistry
|
January 30, 2009
Discovery of (2S,4R)-1-(2-aminoacetyl)-4-benzamidopyrrolidine-2-carboxylic acid hydrochloride (GAP-134)13, an orally active small molecule gap-junction modifier for the treatment of atrial fibrillation
John A Butera, Bjarne Due Larsen, James K Hennan, et al.
Stem Cells and Development
|
July 28, 2016
Induced Pluripotent Stem Cell Differentiation and Three-Dimensional Tissue Formation Attenuate Clonal Epigenetic Differences in Trichohyalin
Anastasia Petrova, Antonio Capalbo, Laureen Jacquet, et al.
Journal of Pharmaceutical Sciences
|
September 21, 2017
Industry Perspective on Contemporary Protein-Binding Methodologies: Considerations for Regulatory Drug-Drug Interaction and Related Guidelines on Highly Bound Drugs
Li Di, Christopher Breen, Rob Chambers, et al.
Journal of Medicinal Chemistry
|
August 20, 2010
Discovery of 2-[1-(4-chlorophenyl)cyclopropyl]-3-hydroxy-8-(trifluoromethyl)quinoline-4-carboxylic acid (PSI-421), a P-selectin inhibitor with improved pharmacokinetic properties and oral efficacy in models of vascular injury
Adrian Huang, Alessandro Moretto, Kristin Janz, et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals
|
July 2, 2022
<b>Transporter-Enzyme Interplay in the Pharmacokinetics of PF-06835919, A First-in-class Ketohexokinase Inhibitor for Metabolic Disorders and Non-alcoholic Fatty Liver Disease</b>
Yan Weng, Kari R Fonseca, Yi-An Bi, et al.
CNS Neuroscience & Therapeutics
|
February 20, 2025
Clinical Features of Glutamic Acid Decarboxylase-65 Neurological Autoimmunity: A Case Series From China
Zhandong Qiu, Fang Xu, Mengyao Zhang, et al.
Pharmaceutical Research
|
April 12, 2022
Unbound Brain-to-Plasma Partition Coefficient, K<sub>p,uu,brain</sub>-a Game Changing Parameter for CNS Drug Discovery and Development
Irena Loryan, Andreas Reichel, Bo Feng, et al.
Page
of 30
Search research articles
Search
Showing results (251-260 of 293) with videos related to
Sort By:
Page
of 30
Journal of Neurology
|
September 8, 2025
Factors associated with early response to efgartigimod in patients with generalized myasthenia gravis: a multicenter retrospective observational study
Wenjia Zhu, Yuping Chen, Cong Tian, et al.
Molecular Cancer
|
May 1, 2025
Multi‑omics analysis identifies different molecular subtypes with unique outcomes in early-stage poorly differentiated lung adenocarcinoma
Bing Liu, Wei Tao, Xuantong Zhou, et al.
Journal of Medical Genetics
|
November 3, 2023
Non-coding CGG repeat expansion in <i>LOC642361/NUTM2B-AS1</i> is associated with a phenotype of oculopharyngodistal myopathy
Xinyu Gu, Jiaxi Yu, Kexin Jiao, et al.
Journal of Medicinal Chemistry
|
January 30, 2009
Discovery of (2S,4R)-1-(2-aminoacetyl)-4-benzamidopyrrolidine-2-carboxylic acid hydrochloride (GAP-134)13, an orally active small molecule gap-junction modifier for the treatment of atrial fibrillation
John A Butera, Bjarne Due Larsen, James K Hennan, et al.
Stem Cells and Development
|
July 28, 2016
Induced Pluripotent Stem Cell Differentiation and Three-Dimensional Tissue Formation Attenuate Clonal Epigenetic Differences in Trichohyalin
Anastasia Petrova, Antonio Capalbo, Laureen Jacquet, et al.
Journal of Pharmaceutical Sciences
|
September 21, 2017
Industry Perspective on Contemporary Protein-Binding Methodologies: Considerations for Regulatory Drug-Drug Interaction and Related Guidelines on Highly Bound Drugs
Li Di, Christopher Breen, Rob Chambers, et al.
Journal of Medicinal Chemistry
|
August 20, 2010
Discovery of 2-[1-(4-chlorophenyl)cyclopropyl]-3-hydroxy-8-(trifluoromethyl)quinoline-4-carboxylic acid (PSI-421), a P-selectin inhibitor with improved pharmacokinetic properties and oral efficacy in models of vascular injury
Adrian Huang, Alessandro Moretto, Kristin Janz, et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals
|
July 2, 2022
<b>Transporter-Enzyme Interplay in the Pharmacokinetics of PF-06835919, A First-in-class Ketohexokinase Inhibitor for Metabolic Disorders and Non-alcoholic Fatty Liver Disease</b>
Yan Weng, Kari R Fonseca, Yi-An Bi, et al.
CNS Neuroscience & Therapeutics
|
February 20, 2025
Clinical Features of Glutamic Acid Decarboxylase-65 Neurological Autoimmunity: A Case Series From China
Zhandong Qiu, Fang Xu, Mengyao Zhang, et al.
Pharmaceutical Research
|
April 12, 2022
Unbound Brain-to-Plasma Partition Coefficient, K<sub>p,uu,brain</sub>-a Game Changing Parameter for CNS Drug Discovery and Development
Irena Loryan, Andreas Reichel, Bo Feng, et al.
Page
of 30